Malignant Female Reproductive System Neoplasm, Gynecologic Cancer, Gynecologic Neoplasm
Conditions
Keywords
Frailty, Risk Factors
Brief summary
This study seeks to understand how frailty, a term that describes people who are more vulnerable stressors such as a new medical problem, affects the outcomes and quality of life in adult patients with gynecologic cancer.
Detailed description
PRIMARY OBJECTIVE: I. Assess the risk factors associated with frailty in newly diagnosed gynecologic cancer participants. SECONDARY OBJECTIVES: I. Compare primary quality of life endpoint of "healthy days at home" between non-frail and frail participants (primary quality of life endpoint). II. Compare other perioperative, oncologic, and quality of life outcomes between non-frail and frail participants. OUTLINE: This is an observational study. All new patients being evaluated for a new diagnosis of gynecologic cancer by the University of California, San Francisco (UCSF) Gynecologic Oncology service and the Dana-Farber Cancer Institute will be recruited in both the outpatient or inpatient setting. Study participants will be enrolled at the time of diagnosis and followed for up to one year after undergoing surgery for cancer.
Interventions
Physical assessments of frailty will be conducted in person.
OTHERSelf-reported Assessments and Questionnaires
Quality of life questionnaires and self-reported measures will be provided to complete during the course of the study
PROCEDURESurgery (Standard of Care, Non-Interventional)
Surgical data will be reviewed via medical record
Sponsors
University of California, San Francisco
Conquer Cancer Foundation
American Society of Clinical Oncology
National Institute on Aging (NIA)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 18 years or greater * Undergoing evaluation for a newly diagnosed gynecologic malignancy * Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it
Exclusion criteria
* Contraindication to any study-related procedure or assessment * Does not speak a language for which the consent form and study materials are available
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of participants who are categorized as frail | At time of enrollment, 1 day | The Fried frailty phenotype (FP) assesses physical frailty through five criteria: unintentional weight loss; weakness or poor handgrip strength; self-reported exhaustion; slow walking speed; and low physical activity. Participants who receive a score of \>3 will be categorized as 'frail'. Participants who receive a score \<=3 will be categorized as Non-frail at time of enrollment. |
| Demographic risk factors associated with those who screen positive for frailty | At time of enrollment, 1 day | Demographic risk factors obtained from medical record review (i.e. sex, age, race, ethnicity, cancer type, cancer histology, cancer stage, comorbidities, etc.) will be assessed and analyzed for differences between participants categorized as frail versus non-frail. |
| Oncologic risk factors associated with those who screen positive for frailty | At time of enrollment, 1 day | Risk factors determined to be oncologic in nature will be assessed and analyzed for differences between participants categorized as frail versus non-frail. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean number of healthy days at home | Up to 10 years | The number of healthy days at home is defined as healthy days at home is defined as: 365 days minus (1) mortality days, (2) total number of days spent in inpatient, observation, skilled nursing facilities (SNF), rehabilitation, long-term hospital settings, emergency department and will be summarized and used as covariate in analysis. |
| Mean length of hospital stay | Up to 10 years | The number of days participants stay in the hospital following standard of care surgery for gynecological cancer will be summarized and used as covariate in analysis. |
| Percentage of participants readmitted to hospital | Up to 10 years | Participants with documented re-admission to a hospital following standard of care surgery for gynecological cancer will be summarized and used as a covariate in analysis. |
| Percentage of participants with reported surgical complications | Up to 10 years | Participants with documented peri-operative complications following standard of care surgery for gynecological cancer will be summarized and used as a covariate in analysis. |
| Mean time to initiation of standard of care chemotherapy | Up to 10 years | The median number of days following standard of care surgery for gynecological cancer to first standard of care chemotherapy initiation will be summarized and used as a covariate in analysis. |
| Median Progression Free Survival (PFS) | Up to 10 years | Progression free survival is defined as the time from date of diagnosis to date of radiographic progression, and/or doubling of cancer antigen 125 (CA-125) from baseline. |
| Median Overall Survival (OS) | Up to 10 years | Overall survival as defined by days from date of diagnosis to date of death, or study completion whichever occurs first. |
| Mean number of treatment delays | Up to 10 years | Chemotherapy delays is defined by the number of chemotherapy infusions that are delayed due for medical purposes and the total number of days infusions are delayed for will be summarized and used as a covariate in analysis. |
Countries
United States
Contacts
CONTACTJanet Titzler
PRINCIPAL_INVESTIGATORStephanie Cham, MD
University of California, San Francisco
Outcome results
None listed